Excess porphyrin formation following administration of inhibitors of the biosynthesis of ATP.
D000227:Adenine Nucleotides; D000255:Adenosine Triphosphate / Q000096:biosynthesis*; D000818:Animals; D000963:Antimetabolites / Q000494:pharmacology*; D004912:Erythrocytes; D005001:Ethionine / Q000494:pharmacology*; D066298:In Vitro Techniques; D015122:Mercaptopurine / Q000494:pharmacology*; D009963:Orotic Acid / Q000494:pharmacology*; D011166:Porphyrins / Q000096:biosynthesis*; D051381:Rats
D000227:Adenine Nucleotides; D000963:Antimetabolites; D011166:Porphyrins; D009963:Orotic Acid; D000255:Adenosine Triphosphate; D015122:Mercaptopurine; D005001:Ethionine